MarketWatch

Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue ...
Ophthalmology Times

FDA grants orphan drug designation to DSP-3077 for retinitis pigmentosa

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor c urrently in Phase 1/2 development for ...
Nasdaq

Ocugen Reports Positive Two-Year Safety and Efficacy Results for OCU400 in Phase 1/2 Clinical Trial for Retinitis Pigmentosa

OCU400 shows significant long-term improvements in visual function and mobility for retinitis pigmentosa patients, with a strong safety profile. Ocugen, Inc. announced positive results from its Phase ...
Business Wire

VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology ...

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) ...
Healio

AURN001 cell therapy achieves primary endpoint of visual acuity improvement at 12 months

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The allogenic cell therapy achieved all primary and ...
Ophthalmology Times

Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...
FierceBiotech

Nuvalent shares lung cancer data, sparking race to FDA for would-be Pfizer rival

Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena. The ALKOVE ...
ascopubs.org

Phase 1/2 study of the trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) as monotherapy or combination therapy in ...

MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO ...
ascopubs.org

LEGEND: A phase 1/2 study of detalimogene voraplasmid (EG-70), an intravesical monotherapy for patients with high-risk non–muscle-invasive bladder cancer (NMIBC).

ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy—A randomized, open-label, phase 2 study. This is an ASCO Meeting Abstract ...